• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines

Professional Introduction to 2-(oxan-4-yl)morpholine (CAS No. 1521982-50-2)

2-(oxan-4-yl)morpholine, identified by the chemical abstracts service number 1521982-50-2, is a significant compound in the field of pharmaceutical chemistry and drug development. This heterocyclic amine derivative has garnered attention due to its unique structural properties and potential applications in medicinal chemistry. The compound features a morpholine ring linked to an oxane moiety, which creates a rigid yet flexible framework that may enhance its interaction with biological targets.

The synthesis of 2-(oxan-4-yl)morpholine involves multi-step organic transformations, typically starting from readily available precursors such as morpholine and epichlorohydrin. The introduction of the oxane ring through nucleophilic substitution or cyclization reactions introduces a new level of conformational control, making it a valuable scaffold for designing novel bioactive molecules. The presence of both nitrogen and oxygen atoms in the structure allows for diverse hydrogen bonding interactions, which can be exploited in drug-receptor binding studies.

In recent years, 2-(oxan-4-yl)morpholine has been explored as a key intermediate in the development of small-molecule drugs targeting various therapeutic areas. One notable application is in the design of kinase inhibitors, where the morpholine ring serves as a pharmacophore to engage with ATP-binding pockets. The oxane substituent, on the other hand, can modulate solubility and metabolic stability, critical factors in drug optimization.

Recent studies have highlighted the potential of 2-(oxan-4-yl)morpholine in addressing neurological disorders. Researchers have demonstrated that derivatives of this compound exhibit promising activity against enzymes involved in neurodegenerative pathways. The structural motif is particularly effective in mimicking natural substrates or modulating enzyme kinetics, thereby offering a therapeutic edge. For instance, modifications to the morpholine nitrogen or the oxane oxygen have shown enhanced binding affinity to specific protein targets, paving the way for next-generation neuroprotective agents.

The pharmaceutical industry has also leveraged 2-(oxan-4-yl)morpholine in the development of antiviral and antibacterial agents. Its ability to penetrate biological membranes and interact with viral proteases or bacterial enzymes makes it a versatile building block. By incorporating functional groups such as halogens or amides into the core structure, chemists have synthesized compounds with improved efficacy against resistant strains. This adaptability underscores the compound's significance as a pharmacological platform.

From a computational chemistry perspective, 2-(oxan-4-yl)morpholine has been subjected to extensive molecular modeling studies to elucidate its binding mechanisms. Advanced techniques like molecular dynamics simulations and quantum mechanical calculations have provided insights into how this compound interacts with biological macromolecules at an atomic level. These findings are crucial for rational drug design, enabling researchers to fine-tune properties such as lipophilicity and polar surface area to optimize pharmacokinetic profiles.

The environmental impact of 2-(oxan-4-yl)morpholine during synthesis and application is another area of interest. Green chemistry principles have been applied to develop more sustainable synthetic routes, minimizing waste and hazardous byproducts. For example, catalytic methods using transition metals have been employed to enhance reaction efficiency while reducing energy consumption. Such innovations align with global efforts to promote sustainable pharmaceutical manufacturing.

Future directions in research on 2-(oxan-4-yl)morpholine include exploring its role in targeted drug delivery systems. Nanotechnology-based platforms have been investigated for encapsulating this compound, allowing for controlled release profiles that could improve therapeutic outcomes. Additionally, bioconjugation strategies involving peptide linkers or antibodies are being explored to enhance specificity and reduce off-target effects.

In conclusion, 2-(oxan-4-yl)morpholine (CAS No. 1521982-50-2) represents a compelling example of how structural innovation can drive advancements in drug discovery. Its unique combination of chemical features makes it a versatile scaffold for addressing diverse therapeutic challenges. As research continues to uncover new applications and synthetic methodologies, this compound is poised to remain at the forefront of pharmaceutical innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)